Technology | Lung Cancer | October 05, 2018

Body Vision Medical Announces Release of LungVision

Platform creates augmented reality to see fluoroscopically invisible lung lesions

Body Vision Medical Announces Release of LungVision

October 5, 2018 — Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its LungVision platform. The platform will be presented at the CHEST conference, Oct. 7-10 in San Antonio, Texas.

"Body Vision provides a great tool that has changed the way we approached peripheral nodules. Its unique technology creates augmented reality with the ability to see fluoroscopically invisible lesions and the pathways under the live fluoro, while tracking a patient breathing," said D. Kyle Hogarth, M.D., FCCP, president of the Society for Advanced Bronchoscopy, associate professor of medicine, director of bronchoscopy at the University of Chicago. "Once the technology has guided us to the lesion, we confirm the lesion's relationship to the airway with radial-EBUS [endobronchial ultrasound]. We then use our off-the-shelf biopsy instruments via the LungVision catheter. The augmented fluoro image, integrated with the radial EBUS images, allows us to obtain tissue samples with continuous real-time confirmation of location. The beauty of it all is how simple and elegant the technology is."

Body Vision CEO Dorian Averbuch said the product targets small pulmonary nodules that, if diagnosed early, can be resected to cure lung cancer. The technology provides step-by-step guidance through planning, navigation and lesion localization during biopsy.

The clinical experience with the LungVision platform will be featured through the following panel presentations during the CHEST conference at San Antonio, TX:

  • Sun. Oct. 7
    • Krish Bhadra, M.D., Novel Augmented Fluoroscopic Imaging Platform Accuracy Assessment during Navigation Bronchoscopy in Simultaneous Comparison with Cone Beam CT and Radial EBUS
    • D. Kyle Hogarth, M.D., FCCP, A Novel Endobrachial Fluoroscopic Navigation and Localization System: a summary of a multi-center LungVision Trial
  • Tue., Oct. 9
    • Patrick E. Whitten, M.D., FCCP, Augmented Endobronchial Fluoroscopic Navigation and Localization System: Integration of Multimodalities and Biopsy Tools to Increase Diagnostic Yield

For more information: www.bodyvisionmedical.com

Related Content

The radiology industry is saddened to learn of the passing of another leader to COVID-19. Franklin Wilfred Sequeira, M.D., 72, of Cicero, Ind., passed away June 1, 2020. He was just short of celebrating his 40th year working with Radiology of Indiana as an interventional radiologist, never missing a day of work.

Franklin Wilfred Sequeira, M.D.

News | Coronavirus (COVID-19) | June 13, 2020
June 13, 2020 — The r
Chief among the myriad practical updates to minimize risks for patients and imaging personnel alike is a tiered approach for delaying both outpatient and inpatient cross-sectional interventional procedures

For procedural delays that will not adversely affect patient outcome, Fananapazir and colleagues proposed the following tiered approach for both outpatient and inpatient scenarios: urgent procedures, procedures that should be performed within 2 weeks, procedures that should be performed within 2 months, and procedures that can safely be delayed 2 or 6 months. Courtesy of American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | June 05, 2020
June 5, 2020 — An...
The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

News | Coronavirus (COVID-19) | May 26, 2020
May 26, 2020  — Philips Healthcare recently received 510(k) clearance from the U.S.
In a new study to help oncologists address the challenges COVID-19-positive lung cancer patients present, a team of global lung cancer specialists published a review of lung cancer treatments for patients with COVID-19

Getty Images

News | Coronavirus (COVID-19) | May 18, 2020
May 18, 2020 — Lung cancer patients are at heightened risk for...
#gadolinium Guerbet announced that it received U.S. Food and Drug Administration (FDA) approval to manufacture Dotarem (gadoterate meglumine) injection at its Raleigh, N.C., facility
News | Interventional Radiology | April 21, 2020
April 21, 2020 — Guerbet announced that it received U.S.